Back to search

United Kingdom· GB-APID-39334111000001108

Allergy Relief 8mg capsules

A acrivastine product containing acrivastine, registered in United Kingdom by Brown & Burk UK Ltd. The same ATC class is registered in 4 of our 19 countries.

ATC R06AX18

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedAllergy Relief 8mg capsulesATCR06AX18REGISTER NO.GB-APID-3933411100000…PACKS LISTED1CHECKEDSeptember 13, 2026

Where it is registered

Acrivastine is registered in 4 of 19 countries.

Countries holding a registration under ATC R06AX18 (acrivastine), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 1 of them publish a price we can compare per daily dose

Acrivastine · ATC R06AX18

4 / 19 countries

  • Denmark
  • Finlandprice
  • Netherlands
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Acrivastine
Manufacturer
Brown & Burk UK Ltd
Country
United Kingdom (GB)
ATC code
R06AX18
ATC class
Acrivastine
Defined daily dose
24 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 1

  • gtin
    5060124641522

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

156 interactions on record for acrivastine.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Acrivastine · interactions on record

156 records

  • 8 severe
  • 146 moderate
  • 2 minor

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • Sodium oxybateN01AX11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Acrivastine in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All acrivastine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Denmark · Allergone, Benadryl
  • Finland · Benadryl
  • Netherlands · Semprex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d3b5cb85-54af-4c77-8f02-80eb46223afe
GET /v1/drugs/d3b5cb85-54af-4c77-8f02-80eb46223afe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "39334111000001108",
  "desc": "Allergy Relief 8mg capsules (Brown & Burk UK Ltd)",
  "form": "Oral capsule",
  "vpid": "42184011000001104",
  "source": "dmd",
  "vtm_id": "774431006",
  "strength": "8 mg",
  "substance": "Acrivastine",
  "ingredient": "Acrivastine",
  "supplier_code": "32392811000001109"
}

See everything about acrivastine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.